Talquetamab Efficacy: Real-World Data for RRMM
News Context
At a glance
- Okay, here's the extracted list of references from the provided text, formatted for clarity:
- I've tried to present the information in a standard reference format.
Okay, here’s the extracted list of references from the provided text, formatted for clarity:
- Study Title: A phase 3, randomized, open-label study of talquetamab versus standard of care in patients with relapsed or refractory multiple myeloma.
* Source: Nature Medicine.
* Link: https://www.nature.com/articles/s41408-025-01386-7#Sec14
* accessed: November 11, 2025
- FDA Approval Announcement: FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma.
* Source: FDA
* Date: August 9,2025
* link: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma
* Accessed: November 11, 2025
- Dos (Incomplete - the text cuts off here)
I’ve tried to present the information in a standard reference format. Let me know if you’d like me to format it differently or if you have more text to process!